Chris Smith

Chris Smith is a seasoned investment professional with extensive experience in the biotechnology and pharmaceutical sectors. Currently a Partner and Investment Director at Brandon Capital since November 2012, Chris has held various titles including Senior Investment Manager and Investment Manager. In addition to roles at Brandon Capital, Chris serves as a Director at several companies, including Denteric Pty Ltd, Paragen Bio, Okogen, MecRx Pty Ltd, Aravax, and Ena Therapeutics Pty Ltd, contributing to the development of innovative therapies for cancer, peanut allergy, and respiratory infections. Chris has also held executive positions at Q-Sera and Solvanix, focusing on advancements in blood collection technology and antibody stability. Prior to these roles, Chris worked as a Business Development Manager at CSL. Educational qualifications include an MBA from the University of Cambridge, a PhD in Immunology from the Walter and Eliza Hall Institute, and a Bachelor of Science in Microbiology and Immunology from the University of Melbourne.